Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CTP-miRNA
- Development stage
- Preclinical
- Lead developer
- Vivasc Therapeutics
- Modality
- miRNA Mimics → MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, miRNA Inhibitors → MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
**CTP-miRNA** is a preclinical, cardiomyocyte-targeted RNA therapeutic consisting of Vivasc Therapeutics' cardiac targeting peptide linked through a reversible disulfide bond to microRNA-106a. The conjugate is designed to preferentially deliver miRNA106a to cardiomyocytes, where the RNA cargo suppresses pathological hypertrophy- and inflammation-associated gene expression, including phospholipase C beta 1 and calcium/calmodulin-dependent protein kinase II delta signaling. In cell and mouse heart-failure models, CTP-miRNA106a reduced cardiomyocyte hypertrophy and improved cardiac functional measures; it is being developed for heart failure and cardiac hypertrophy. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12358689/))
- Other names
- CTP-miRNA106aCTP-miRNA-106aCTP-miRNA 106a
02
Targets
CAMK2D (Calcium/calmodulin-dependent protein kinase II delta)HDAC4PLCB1 (Phospholipase C beta 1)
Beyond the preview
Go deeper on CTP-miRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CTP-miRNA.